Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 1,662 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 167
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES
US14.01.2010
12282504Kolodney Michael S.
C12Q 1/68
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids

In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes.


Preparation method of dianhydride monomer containing chiral dianhydro-hexitol
CN17.02.2010
200910092469.1Tsinghua UniversityChen Zhen
C07D 493/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
The invention relates to a preparation method of dianhydride monomer containing chiral dianhydro-hexitol, belonging to the technical field of high polymer materials. The preparation method comprises the following steps: adding chiral dianhydro-hexitol into anhydrous solvent according to the mol ratio between the chiral dianhydro-hexitol and the solvent of 1: 30-40; adding acid absorbent into chiral dianhydro-hexitol solution according to the mol ratio between the chiral dianhydro-hexitol and the acid absorbent of 1: 1-1.2; adding 1,2,4-trimellitic anhydride acyl chloride into the mixture according to the mol ratio between the chiral dianhydro-hexitol and the 1,2,4-trimellitic anhydride acyl chloride of 1: 2.1-2.4, reacting under stirring at a temperature between 0 DEG C and room temperature; carrying out air pump filtration on the reactant, slowly dripping filtrate into petroleum ether, and separating white solid out. The preparation method has the advantages of low material cost, mildpreparation reaction conditions, easy control, high reaction conversion ratio and simpler purification after reaction.

METHOD FOR PRODUCING AZIDE SUGAR BY MICROORGANISM REACTION AND ENZYME REACTION
JP28.01.2010
2008181469KISHOTO SEISAN GIJUTSU KENKYUSHO:KKIKUMORI TAKESHI
C12N 9/02
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
9
Enzymes, e.g. ligases (6.); Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating, or purifying enzymes
02
Oxidoreductases (1.), e.g. luciferase
PROBLEM TO BE SOLVED: To provide a bacterium that belongs to the genus Klebsiella and has ability of producing L-tagatose from galactitol.

SOLUTION: The bacterium of the genus Klebsiella has ability of using 6-azide hexitol as a raw material in which the 6-position of hexose is azidated, oxidizing the 2-position and forming 6-azide ketohexose. Moreover, the bacterium of the genus Klebsiella has ability of isomerizing 6-azide ketohexose and producing 6-azide aldohexose. The 6-azide polyol dehydrogenase is produced by the bacterium, acts on 6-azide polyol and oxidizes the 2-position to give ketose so as to form 6-azide ketohexose. The 6-azide aldose isomerase isomerizes 6-azide ketohexose to produce 6-azide aldohexose.

COPYRIGHT: (C)2010,JPO&INPIT


プレガバリンを含有する安定化された医薬組成物
JP22.07.2010
2010504536ラシオファルム ゲーエムベーハーシュルツェナールプ、ジュリア
A61K 47/04
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
02
Inorganic compounds
04
Non-metals; Compounds thereof

(a)活性成分としてのプレガバリン、及び(b)1種又は数種の医薬補助剤を含有する固体医薬組成物であって、糖類を本質的に含まず、プレガバリンは別として、それ以外のアミノ酸を含まない組成物。


СТАБИЛИЗИРОВАННАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРЕГАБАЛИН
EA30.04.2010
200901365РАЦИОФАРМ ГМБХШульце-Наруп Юлия
A61K 9/16
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
16
Agglomerates; Granulates; Microbeadlets

Твердая фармацевтическая композиция, содержащая: (a) прегабалин в качестве действующего вещества и (b) одно или несколько фармацевтических вспомогательных веществ, при этом композиция, по существу, не содержит сахариды и не содержит дополнительные аминокислоты кроме прегабалина.


Stabilised pharmaceutical composition containing pregabaline
CN03.03.2010
200880012632.2Ratiopharm GmbHSchulze-nahrup Julia
A61K 9/16
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
14
Particulate form, e.g. powders
16
Agglomerates; Granulates; Microbeadlets
Solid pharmaceutical composition containing: (a) pregabaline as active principle and (b) one or several pharmaceutical auxiliary agents, the composition being essentially free from saccharides and comprising no further amino acids, apart from pregabaline.

Dbaitおよびその単独使用
JP13.05.2010
2009545182サントル・ナショナル・ドゥ・ラ・ルシェルシュ・シャンティフィクデユトレックス,マリー
C12N 15/113
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

本発明は、哺乳動物細胞における二本鎖切断(DSB)のDNA修復に干渉する組成物および方法に関する。本発明は、DNA DSB検知、シグナル伝達および/または修復経路、特にDSB修復の非相同末端結合(NHEJ)経路に関与する酵素のホロ複合体(holocomplex)を引き寄せる、または、奪うことにより作用する二本鎖核酸分子を開示する。本発明は、死を誘発するために、有効量で腫瘍細胞の核に導入される単独の抗癌薬物としてのこれらの分子の使用を開示する。


Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US03.06.2010
12117872IDEXX Laboratories, Inc.Krah, III Eugene Regis
A61K 39/395
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

The invention provides methods and compositions for inhibiting binding of IgE to a high affinity receptor. The methods and compositions are useful in the treatment of allergic diseases and allergy symptoms in mammals.


NUTRITIONAL SUPPLEMENT
US04.02.2010
12516639Wittenbaker Neville Trevor
A61K 35/56
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
56
Materials from animals other than mammals or birds

A nutritional supplement derived from skeletal tissue found in bony and cartilaginous fish has been found to be useful in the treatment of mineral deficiencies, in particular calcium deficiency, and additionally, in the treatment of arthritis, kidney stones, and gout in animals, including humans. A nutritional supplement composition and a pharmaceutical composition containing the nutritional supplement are also provided. The nutritional supplement contains 300,000 to 400,000 mg/kg calcium, 100 to 150 mg/kg phosphorous, 10 to 20 mg/kg magnesium, and 1,500 to 2,000 mg/kg sodium.


NUTRITIONAL SUPPLEMENT
KR10.02.2010
1020097013230WITTENBAKER NEVILLE TREVOR비텐베이커, 네빌, 트레버
A61K 35/60
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35
Medicinal preparations containing material or reaction products thereof with undetermined constitution
56
Materials from animals other than mammals or birds
60
Fish
A nutritional supplement derived from skeletal tissue found in bony and cartilaginous fish has been found to be useful in the treatment of mineral deficiencies, in particular calcium deficiency, and additionally, in the treatment of arthritis, kidney stones, and gout in animals, including humans. A nutritional supplement composition and a pharmaceutical composition containing the nutritional supplement are also provided. The nutritional supplement contains 300,000 to 400,000 mg/kg calcium, 100 to 150 mg/kg phosphorous, 10 to 20 mg/kg magnesium, and 1,500 to 2,000 mg/kg sodium. COPYRIGHT KIPO WIPO 2010

Results 1-10 of 1,662 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 167